Zydus Cadila receives USFDA nod for Atenolol, Chlorthalidone Tablets to treat high BP

Atenolol and Chlorthalidone Tablets will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad, Zydus Cadila said in a statement.

Mumbai: Pharma major Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Atenolol and Chlorthalidone Tablets 50 mg/25 mg and 100 mg/25 mg, used to treat high blood pressure, in the US.

The company has received approval from the USFDA to market the medication in two different strengths, Zydus Cadila said in a statement. It will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.

This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.

Also Read: Zydus Cadila gets USFDA nod to Potassium Chloride ER Capsules to prevent hypokalemia

Atenolol belongs to a class of drugs known as beta blockers. It works by blocking the action of certain natural chemicals in body, such as epinephrine on the heart and blood vessels. This effect lowers the heart rate, blood pressure and strain on the heart.

Chlorthalidone is a 'water pill' (diuretic) and causes the body to get rid of extra salt and water. It also helps to relax the blood vessels, so that blood can flow easily.

The group now has 253 approvals and has so far filed over 330 ANDAs, since the commencement of the filing process in FY 2003-04.

The company is headquartered at Ahmedabad in Gujarat state of western India.

Also Read: Zydus Cadila gets USFDA nod to Doxazosin for treating BP, enlarged prostate issues